Organization and Business	6 Months Ended
Jun. 30, 2026
Organization and Business [Abstract]
ORGANIZATION AND BUSINESS	NOTE 1 – ORGANIZATION AND BUSINESS Silo Pharma, Inc. (the “Company”) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On May 21, 2019, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter, on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Uppercut Brands, Inc. to Silo Pharma, Inc. On January 24, 2013, the Company changed its state of incorporation from New York to Delaware and on December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of Nevada. On April 8, 2020, the Company incorporated a new wholly-owned subsidiary, Silo Pharma Inc., in the State of Florida. On April 15, 2026, the Company formed Qwikagentsai Inc. (“Qwikagentsai”), a Nevada corporation, as a wholly-owned subsidiary. Qwikagentsai was formed to diversify the Company’s business into artificial intelligence (“AI”) technology including the development and commercialization of web-based AI agent platforms. The Company is a developmental-stage biopharmaceutical company with a cryptocurrency treasury strategy. The Company’s therapeutic focus is on developing novel therapeutics that address underserved conditions including post-traumatic stress disorder (“PTSD”), stress-induced anxiety disorders, fibromyalgia, and central nervous system (“CNS”) diseases. The Company is focused on developing (i) an intranasal drug targeting PTSD and stress-induced anxiety disorders (SPC-15); (ii) a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief (SP-26); (iii) an intranasal compound for the treatment of Alzheimer’s disease (SPC-14); and (iv) a CNS-homing peptide targeting the central nervous system in multiple sclerosis (SPU-16). Qwikagentsai is an AI-agent platform focused on enterprise workflow automation through autonomous AI agents. The platform combines persistent memory, intelligent model routing across eight large language model providers, encrypted backups, and browser automation to support scalable AI-driven operations. On June 1, 2026, the Company filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share. The Reverse Stock Split became effective on June 2, 2026 and the Company’s common stock began trading on a split-adjusted basis at the open of business on June 3, 2026. All share and per share data in the unaudited consolidated financial statements have been retroactively adjusted to reflect the effect of the reverse stock split.

Organization and Business

6 Months Ended

Jun. 30, 2026

Organization and Business [Abstract]

NOTE 1 – ORGANIZATION AND BUSINESS

Silo Pharma, Inc. (the “Company”) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On May 21, 2019, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter, on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Uppercut Brands, Inc. to Silo Pharma, Inc. On January 24, 2013, the Company changed its state of incorporation from New York to Delaware and on December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of Nevada.

On April 8, 2020, the Company incorporated a new wholly-owned subsidiary, Silo Pharma Inc., in the State of Florida.

On April 15, 2026, the Company formed Qwikagentsai Inc. (“Qwikagentsai”), a Nevada corporation, as a wholly-owned subsidiary. Qwikagentsai was formed to diversify the Company’s business into artificial intelligence (“AI”) technology including the development and commercialization of web-based AI agent platforms.

The Company is a developmental-stage biopharmaceutical company with a cryptocurrency treasury strategy. The Company’s therapeutic focus is on developing novel therapeutics that address underserved conditions including post-traumatic stress disorder (“PTSD”), stress-induced anxiety disorders, fibromyalgia, and central nervous system (“CNS”) diseases. The Company is focused on developing (i) an intranasal drug targeting PTSD and stress-induced anxiety disorders (SPC-15); (ii) a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief (SP-26); (iii) an intranasal compound for the treatment of Alzheimer’s disease (SPC-14); and (iv) a CNS-homing peptide targeting the central nervous system in multiple sclerosis (SPU-16). Qwikagentsai is an AI-agent platform focused on enterprise workflow automation through autonomous AI agents. The platform combines persistent memory, intelligent model routing across eight large language model providers, encrypted backups, and browser automation to support scalable AI-driven operations.

On June 1, 2026, the Company filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share. The Reverse Stock Split became effective on June 2, 2026 and the Company’s common stock began trading on a split-adjusted basis at the open of business on June 3, 2026. All share and per share data in the unaudited consolidated financial statements have been retroactively adjusted to reflect the effect of the reverse stock split.